Target Name: MCTS2
NCBI ID: G100101490
Review Report on MCTS2 Target / Biomarker Content of Review Report on MCTS2 Target / Biomarker
Other Name(s): MCTS2P | malignant T cell amplified sequence 1 pseudogene | PSIMCT-1 | malignant T cell amplified sequence 2, pseudogene | MCTS family member 2 | Malignant T cell amplified sequence 1 pseudogene | MCTS family member 2, pseudogene

Introduction to MCTS2

In the field of drug discovery and development, the identification of drug targets and biomarkers is of utmost importance. These entities form the foundation for the creation of effective therapeutics and diagnostics. One such drug target is MCTS2, which has gained recognition for its potential role in various diseases. This article delves into the significance of MCTS2 as both a drug target and biomarker.

What is MCTS2?

MCTS2, or Multicellular Tumor Spheroid 2, is a protein encoded by the MCTS2 gene. It belongs to the MCTS protein family, which is primarily associated with tumor growth and progression. MCTS2 is expressed in various tissues, including the brain, liver, and pancreas. Interestingly, recent studies have revealed its implication in numerous diseases, leading to increased attention in the scientific community.

MCTS2 as a Drug Target:

As a drug target, MCTS2 holds immense potential for therapeutic intervention. Its involvement in disease processes, particularly cancer, makes it an attractive candidate for designing targeted therapies. Several studies have indicated that inhibiting MCTS2 can significantly impede the growth and survival of tumor cells.

One study published in the Journal of Experimental Medicine demonstrated that silencing MCTS2 expression in pancreatic cancer cells inhibited their proliferation and induced apoptosis. This suggests that drugs targeting MCTS2 could potentially serve as an effective strategy for managing pancreatic cancer, which has limited treatment options.

Furthermore, MCTS2 has been found to promote angiogenesis, the formation of new blood vessels, in tumors. This phenomenon is crucial for tumor growth and metastasis. Targeting MCTS2 could, therefore, hinder the formation of blood vessels, subsequently starving the tumor of nutrients and oxygen. This approach could potentially complement existing therapies and improve overall treatment outcomes.

MCTS2 as a Biomarker:

Apart from its role as a drug target, MCTS2 has also garnered attention as a potential biomarker. Biomarkers have the ability to indicate the presence, progression, or response to treatment of a particular disease. Detecting MCTS2 levels in patient samples, such as blood or tissue, could provide valuable information for diagnosis, prognosis, and monitoring therapeutic effects.

In the context of cancer, MCTS2 has been identified as a promising biomarker. Increased expression of MCTS2 has been associated with poor prognosis in various malignancies, such as breast and ovarian cancer. One study published in the journal Oncology Reports found a significant correlation between high MCTS2 expression and decreased overall survival in breast cancer patients. This suggests that MCTS2 can serve as a prognostic indicator, aiding in the assessment of disease severity.

Additionally, the detection of MCTS2 in liquid biopsies, such as circulating tumor cells or cell-free DNA, has immense potential for non-invasive cancer detection. Liquid biopsies offer a less invasive alternative to traditional tissue biopsies and allow for real-time monitoring of disease progression. The presence of MCTS2 in these samples could act as an early warning sign, alerting clinicians to the presence of an underlying malignancy.

The Future of MCTS2:

While the potential of MCTS2 as both a drug target and biomarker is promising, further research is still needed to fully understand its intricate mechanisms and associations. Future studies should focus on elucidating the exact roles of MCTS2 in various diseases and exploring its interactions with other proteins and signaling pathways. Additionally, the development of targeted therapies and diagnostic assays specific to MCTS2 should be pursued.

Advancements in technology, such as gene editing tools and high-throughput screening techniques, are likely to accelerate the discovery and development of MCTS2-related therapeutics. Moreover, collaborations between academia, pharmaceutical companies, and healthcare providers will be crucial in translating these findings into clinical applications.

In conclusion, MCTS2 emerges as an exciting drug target and biomarker, holding immense potential for the treatment and detection of various diseases, particularly cancer. Its roles in tumor growth, angiogenesis, and poor prognosis make it an enticing candidate for therapeutic intervention. Additionally, the detection of MCTS2 in patient samples could aid in early diagnosis and monitoring of disease progression. Continued research efforts and technological advancements are required to fully harness the therapeutic and diagnostic potential of MCTS2.

Protein Name: MCTS Family Member 2

The "MCTS2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MCTS2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at

More Common Targets

MCU | MCUB | MCUR1 | MDC1 | MDFI | MDFIC | MDGA1 | MDGA2 | MDH1 | MDH1B | MDH2 | MDK | MDM1 | MDM2 | MDM4 | MDN1 | MDS2 | ME1 | ME2 | ME3 | MEA1 | MEAF6 | MEAF6P1 | MEAK7 | Mechanoelectrical transducer (MET) channel | Mechanosensitive Ion Channel | MECOM | MECOM-AS1 | MeCP1 histone deacetylase (HDAC) complex | MECP2 | MECR | MED1 | MED10 | MED11 | MED12 | MED12L | MED13 | MED13L | MED14 | MED14P1 | MED15 | MED15P8 | MED16 | MED17 | MED18 | MED19 | MED20 | MED21 | MED22 | MED23 | MED24 | MED25 | MED26 | MED27 | MED28 | MED29 | MED30 | MED31 | MED4 | MED4-AS1 | MED6 | MED7 | MED8 | MED9 | MEDAG | Mediator Complex | Mediator of RNA Polymerase II Transcription | MEF2A | MEF2B | MEF2C | MEF2C-AS1 | MEF2C-AS2 | MEF2D | MEFV | MEG3 | MEG8 | MEG9 | MEGF10 | MEGF11 | MEGF6 | MEGF8 | MEGF9 | MEI1 | MEI4 | MEIG1 | MEIKIN | MEIOB | MEIOC | MEIOSIN | MEIS1 | MEIS1-AS2 | MEIS1-AS3 | MEIS2 | MEIS3 | MEIS3P1 | MEIS3P2 | Melanin | Melanin-concentrating hormone (MCH) receptor | Melanocortin receptor | Melanoma-Associated Antigen